 therapeut advanc prevent hepat yeast-deriv recombin hepat vaccin viral hepat second infecti diseas US hepat account major viral hepat case diseas self-limit minim complic signific number individu long-term sequela research util genet engin develop yeast-deriv recombin dna ydr hepat vaccin signific advanc control prevent hepat recombin process product unlimit quantiti vaccin cost potenti threat blood-born ill clinic trial variou high-risk popul effect safeti ydr vaccin question optim regimen need period revaccin remain unansw person risk hepat